# Defu Capital

> Defu Capital is a VC fund backing Medical, Genetics and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Apr 2023
- Lead investor: 100%
- Last updated: Aug 2026

Defu Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Genetics | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series C | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sangon Biotech | Sangon Biotech Co. (生工生物) is engaged in the research and development of chemical synthesis of DNA.It is a high-tech Sino-foreign joint venture established in 2003. After ten years of development, Sangon has become a professional biotechnology company that integrates research and development. Chemical synthesis DNA earned reputation for Sangonin the global market.In 2006, Sangon invested 50 million to build a manufacturing and industrial base in Songjiang Industrial Park, which has been put into use. Sangon produces various products such as DNA synthesis, DNA sequencing, Gene Synthesis, peptide synthesis, chemical agents, enzymes, molecular biology kit, cultivation medium, lab consumptive material, and miniature instruments. | $290.4M | Venture - Series Unknown | Apr 19, 2023 |  |
| Nest | Nest Bio is a manufacturer of disposable medical consumables, focusing on the R&D and production of cell culture consumables. |  | Series A | Jun 07, 2022 |  |
| Bohai New Enzyme | Bohai New Enzyme is a special enzyme research and development manufacturer. | $125M | Series C | Nov 05, 2021 |  |

3 of 3 investments shown.

## Co-investors
- GL Capital — VC Fund, 2 deals together
- Capital Health Fund — VC Fund, 1 deal together
- [CASH Capital](https://shizune.co/investors/profile/cash-capital) — VC Fund, 1 deal together
- CDB Science and Technology Innovation — VC Fund, 1 deal together
- [China Pacific Insurance](https://shizune.co/investors/profile/china-pacific-insurance) — VC Fund, 1 deal together
- [CPE](https://shizune.co/investors/profile/citic-pe) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Defu Capital invest in?

Defu Capital invests primarily in Medical, Genetics and Health Care startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Defu Capital last invest?

The most recent investment recorded for Defu Capital closed in Apr 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co